WP
VNDA icon

WealthShield Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

WealthShield Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150
Closed -$2K – 1151
2021
Q1 		$2K Buy
+150
New +$2.43K ﹤0.01% 1079

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

WealthShield Partners's VNDA Position: Q2 2021 in Review

WealthShield Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2021, closing a stake of 150 shares — an estimated $2K sold.

WealthShield Partners first reported a position in VNDA in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 181 funds tracked by Wall St. Rank hold VNDA as of Q2 2021.

  • WealthShield Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • WealthShield Partners sold 150 Vanda Pharmaceuticals shares in Q2 2021, an estimated $2K.
  • WealthShield Partners first reported a position in Vanda Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • WealthShield Partners's Vanda Pharmaceuticals position peaked at $2K in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2021.

Based on WealthShield Partners's 13F filing for Q2 2021, filed 6 Aug 2021.